南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

基于免疫原性细胞死亡的口腔鳞状细胞癌预后标志物及靶向治疗研究

Research on prognostic markers and targeted therapy for oral squamous cell carcinoma based on immunogenic cell death

Tingru Shao, Xinyan Lu, Xiaogen Zhang, Ruiyu Wang, Chundong Liu, Xiaozhi Lv

Journal:Current Proteomics

IF:1.3

DOI:10.1016/j.curpro.2026.100156

PMID:

Published:2026-09-06

research field:肿瘤学生物信息学免疫治疗药物发现分子生物标志物

Abstract

CTLA4, TNFRSF4, and CD5 are identified as the core prognostic markers for OSCC based on ICD. • The constructed ICD-related prognostic risk model can stratify OSCC patients into significantly distinct risk groups. • Three core prognostic genes are significantly expressed in T cells. • Compound 1 exhibits excellent targeting binding activity towards TNFRSF4. • Compound 1 can activate anti-tumor immunity mediated by CD8 + T cells by targeting TNFRSF4. Background Immunotherapy targets for oral squamous cell carcinoma (OSCC) are scarce. Immunogenic cell death (ICD) mediated anti-tumor immunity provides a new direction for prognosis evaluation and treatment of OSCC, but the related core markers and targeting strategies are not clear. Objectives This study aims to systematically identify ICD-related core prognostic markers for OSCC, construct an effective prognostic risk model, and explore potential targeted immunotherapy strategies against these core markers. Methods In this study, the OSCC transcriptome and single-cell sequencing data of TCGA and GEO databases were integrated. ssGSEA and WGCNA were used to screen the differentially expressed genes related to ICD, and Cox regression was used to construct a prognostic model. The expression characteristics of core genes were verified by single-cell analysis and immunohistochemistry. Drug candidates were screened by DGIdb drug prediction and molecular docking. In vitro cell experiments were performed to verify its regulatory effect on CD8 + T cell-mediated anti-tumor immunity. Results CTLA4, TNFRSF4, and CD5 were selected as core prognostic genes according to the hazard ratio (HR) < 0.7 and the genes with excessive confidence intervals were removed. The risk model constructed in this study could stratify OSCC patients into distinct prognostic groups, with area under the curve (AUC) values for 1-, 2-, and 3-year overall survival reaching 0.625, 0.600, and 0.604 in the training set, and 0.673, 0.667, and 0.661 in the val

本文使用的Yeasen产品

产品应用
购物车
客服
转染试用